Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Virax Biolabs (NASDAQ: VRAX) said its subsidiary Virax Biolabs (UK) signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect RUO immune profiling products. The deal covers six Southeast Asian markets and enables near-term supply via purchase orders, with initial focus on tuberculosis research applications in Thailand. Fosun Pharma reported 2025 revenue of RMB41.662 billion (~US$5.8 billion).
How this was made
The 30-second read
Why it matters
The agreement provides an exclusive, multi-country supply framework with Fosun Diagnostics for ImmuneSelect, enabling immediate execution via purchase orders and setting up phased regional expansion.
Market read
A new exclusive RUO product supply agreement with a major diagnostics group can improve near-term commercialization expectations for Virax’s ImmuneSelect line.
What to watch
Exclusivity is subject to agreed minimum purchase and performance requirements, and the near-term focus is tuberculosis-related research applications in Thailand, which may limit initial revenue breadth.
Background
Virax is developing an in-development diagnostic platform (ViraxImmune) while commercializing an RUO immune profiling product line (ImmuneSelect).
Ticker impact
Virax announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect RUO immune profiling products across six ASEAN markets.
Likely modest positive bias for VRAX on deal headline, with follow-through dependent on actual purchase orders and minimum purchase/performance fulfillment.
The press release discloses a new exclusive supply framework, named markets, and product scope (ELISpot assay plates), but provides no deal size, financial terms, or guaranteed revenue beyond purchase-order execution and stated minimum requirements.
Market effects
Supports the narrative that RUO immune profiling platforms can monetize via established diagnostics distributors in ASEAN.
ASEAN diagnostics distribution expansion could increase competitive intensity for RUO immune profiling suppliers in the region.
If replicated, the Fosun channel could become a template for broader Asia commercialization, but global impact is not quantified here.
Counterpoint
Because the agreement is purchase-order driven and lacks disclosed financial magnitude, the market may discount it until concrete order volumes and minimums are met.
Key entities
- public_companyVirax Biolabs Group Limited
NASDAQ-listed biotech with ImmuneSelect RUO immune profiling products and ViraxImmune in clinical/regulatory development.
- partnerFosun Diagnostics
Regional diagnostics organization and core entity under Fosun Medtech, acting as the commercial partner for ImmuneSelect in six ASEAN markets.
- public_companyFosun Pharma
Parent group of Fosun Medtech; referenced for scale and regional network supporting evaluation and rollout.
